nodes	percent_of_prediction	percent_of_DWPC	metapath
Indomethacin—gout—ankylosing spondylitis	0.431	1	CtDrD
Indomethacin—migraine—Prednisone—ankylosing spondylitis	0.0921	0.341	CpDpCtD
Indomethacin—osteoarthritis—Methylprednisolone—ankylosing spondylitis	0.0891	0.33	CpDpCtD
Indomethacin—osteoarthritis—Prednisone—ankylosing spondylitis	0.0891	0.33	CpDpCtD
Indomethacin—PPARG—Sulfasalazine—ankylosing spondylitis	0.0331	0.135	CbGbCtD
Indomethacin—ABCC11—Methotrexate—ankylosing spondylitis	0.032	0.131	CbGbCtD
Indomethacin—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.0114	0.0466	CbGbCtD
Indomethacin—SLCO1A2—Prednisolone—ankylosing spondylitis	0.0102	0.0418	CbGbCtD
Indomethacin—ABCC2—Sulfasalazine—ankylosing spondylitis	0.00999	0.0409	CbGbCtD
Indomethacin—PTGS2—Sulfasalazine—ankylosing spondylitis	0.00987	0.0404	CbGbCtD
Indomethacin—PTGS2—Triamcinolone—ankylosing spondylitis	0.00987	0.0404	CbGbCtD
Indomethacin—SLCO1A2—Prednisone—ankylosing spondylitis	0.00963	0.0395	CbGbCtD
Indomethacin—ABCC3—Methotrexate—ankylosing spondylitis	0.00882	0.0361	CbGbCtD
Indomethacin—PTGS2—Betamethasone—ankylosing spondylitis	0.00847	0.0347	CbGbCtD
Indomethacin—PTGS1—Sulfasalazine—ankylosing spondylitis	0.00834	0.0341	CbGbCtD
Indomethacin—SLC22A11—Methotrexate—ankylosing spondylitis	0.00724	0.0296	CbGbCtD
Indomethacin—SLC22A7—Methotrexate—ankylosing spondylitis	0.00689	0.0282	CbGbCtD
Indomethacin—ABCC4—Methotrexate—ankylosing spondylitis	0.00674	0.0276	CbGbCtD
Indomethacin—SLCO1A2—Dexamethasone—ankylosing spondylitis	0.00601	0.0246	CbGbCtD
Indomethacin—ABCC1—Methotrexate—ankylosing spondylitis	0.00541	0.0222	CbGbCtD
Indomethacin—ABCC2—Dexamethasone—ankylosing spondylitis	0.00499	0.0204	CbGbCtD
Indomethacin—ALB—Prednisone—ankylosing spondylitis	0.00498	0.0204	CbGbCtD
Indomethacin—PTGS2—Dexamethasone—ankylosing spondylitis	0.00493	0.0202	CbGbCtD
Indomethacin—SLCO1A2—Methotrexate—ankylosing spondylitis	0.00483	0.0198	CbGbCtD
Indomethacin—SLCO1B1—Methotrexate—ankylosing spondylitis	0.00456	0.0187	CbGbCtD
Indomethacin—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0043	0.0176	CbGbCtD
Indomethacin—SLC22A8—Methotrexate—ankylosing spondylitis	0.00421	0.0172	CbGbCtD
Indomethacin—ABCC2—Methotrexate—ankylosing spondylitis	0.00401	0.0164	CbGbCtD
Indomethacin—CYP2C19—Prednisone—ankylosing spondylitis	0.00323	0.0132	CbGbCtD
Indomethacin—PLA2G2A—synovial fluid—ankylosing spondylitis	0.00296	0.47	CbGeAlD
Indomethacin—SLC22A6—Methotrexate—ankylosing spondylitis	0.00293	0.012	CbGbCtD
Indomethacin—ABCB1—Betamethasone—ankylosing spondylitis	0.00279	0.0114	CbGbCtD
Indomethacin—ABCB1—Prednisolone—ankylosing spondylitis	0.00276	0.0113	CbGbCtD
Indomethacin—ABCB1—Prednisone—ankylosing spondylitis	0.0026	0.0107	CbGbCtD
Indomethacin—ALB—Methotrexate—ankylosing spondylitis	0.0025	0.0102	CbGbCtD
Indomethacin—CYP2C19—Dexamethasone—ankylosing spondylitis	0.00201	0.00825	CbGbCtD
Indomethacin—CYP2C9—Dexamethasone—ankylosing spondylitis	0.00167	0.00686	CbGbCtD
Indomethacin—ABCB1—Dexamethasone—ankylosing spondylitis	0.00163	0.00666	CbGbCtD
Indomethacin—PTGDR2—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.00149	0.165	CbGpPWpGaD
Indomethacin—ABCB1—Methotrexate—ankylosing spondylitis	0.00131	0.00535	CbGbCtD
Indomethacin—PTGDR2—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.000987	0.109	CbGpPWpGaD
Indomethacin—PTGDR2—tendon—ankylosing spondylitis	0.000577	0.0918	CbGeAlD
Indomethacin—PTGS2—skeletal joint—ankylosing spondylitis	0.000502	0.0799	CbGeAlD
Indomethacin—PTGR2—tendon—ankylosing spondylitis	0.000383	0.0609	CbGeAlD
Indomethacin—PTGS2—synovial membrane of synovial joint—ankylosing spondylitis	0.000381	0.0607	CbGeAlD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—CREG1—ankylosing spondylitis	0.000349	0.0387	CbGpPWpGaD
Indomethacin—PTGS2—cartilage tissue—ankylosing spondylitis	0.000337	0.0537	CbGeAlD
Indomethacin—PPARA—Orphan transporters—ANO6—ankylosing spondylitis	0.000293	0.0325	CbGpPWpGaD
Indomethacin—GLO1—tendon—ankylosing spondylitis	0.000236	0.0376	CbGeAlD
Indomethacin—PLA2G2A—tendon—ankylosing spondylitis	0.00022	0.035	CbGeAlD
Indomethacin—ABCC11—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000211	0.0234	CbGpPWpGaD
Indomethacin—CXCL8—Overview of nanoparticle effects—CRP—ankylosing spondylitis	0.000179	0.0198	CbGpPWpGaD
Indomethacin—AKR1C3—tendon—ankylosing spondylitis	0.000171	0.0272	CbGeAlD
Indomethacin—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.000168	0.159	CbGdCrCtD
Indomethacin—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000165	0.156	CbGdCrCtD
Indomethacin—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000165	0.156	CbGdCrCtD
Indomethacin—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000161	0.153	CbGdCrCtD
Indomethacin—ABCC6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.00016	0.0177	CbGpPWpGaD
Indomethacin—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000122	0.0135	CbGpPWpGaD
Indomethacin—PPARG—tendon—ankylosing spondylitis	0.000113	0.018	CbGeAlD
Indomethacin—CXCL8—Allograft Rejection—HLA-C—ankylosing spondylitis	0.00011	0.0121	CbGpPWpGaD
Indomethacin—ABCC4—tendon—ankylosing spondylitis	0.000103	0.0163	CbGeAlD
Indomethacin—PTGDR2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000101	0.0112	CbGpPWpGaD
Indomethacin—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000101	0.0958	CbGdCrCtD
Indomethacin—CXCL8—Allograft Rejection—IL17A—ankylosing spondylitis	0.0001	0.0111	CbGpPWpGaD
Indomethacin—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	9.95e-05	0.0942	CbGdCrCtD
Indomethacin—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	9.95e-05	0.0942	CbGdCrCtD
Indomethacin—ABCC2—tendon—ankylosing spondylitis	9.92e-05	0.0158	CbGeAlD
Indomethacin—PTGS1—Overview of nanoparticle effects—CRP—ankylosing spondylitis	9.89e-05	0.011	CbGpPWpGaD
Indomethacin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	9.83e-05	0.0109	CbGpPWpGaD
Indomethacin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	9.73e-05	0.0108	CbGpPWpGaD
Indomethacin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	9.73e-05	0.0108	CbGpPWpGaD
Indomethacin—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	9.72e-05	0.0921	CbGdCrCtD
Indomethacin—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	9.68e-05	0.0107	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—IL12B—ankylosing spondylitis	9.32e-05	0.0103	CbGpPWpGaD
Indomethacin—ABCC1—tendon—ankylosing spondylitis	8.74e-05	0.0139	CbGeAlD
Indomethacin—PTGDR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	8.69e-05	0.00962	CbGpPWpGaD
Indomethacin—PLA2G2A—Spinal Cord Injury—IL1A—ankylosing spondylitis	8.62e-05	0.00955	CbGpPWpGaD
Indomethacin—CXCL8—Overview of nanoparticle effects—TNF—ankylosing spondylitis	8.11e-05	0.00898	CbGpPWpGaD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	8.01e-05	0.00887	CbGpPWpGaD
Indomethacin—PTGS2—Overview of nanoparticle effects—CRP—ankylosing spondylitis	7.85e-05	0.00869	CbGpPWpGaD
Indomethacin—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	7.74e-05	0.00857	CbGpPWpGaD
Indomethacin—CXCL8—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	7.6e-05	0.00842	CbGpPWpGaD
Indomethacin—CXCL8—AP-1 transcription factor network—IL10—ankylosing spondylitis	7.51e-05	0.00832	CbGpPWpGaD
Indomethacin—PPARA—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	7.16e-05	0.00793	CbGpPWpGaD
Indomethacin—SLC22A11—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	6.98e-05	0.00773	CbGpPWpGaD
Indomethacin—CXCL8—EBV LMP1 signaling—TNF—ankylosing spondylitis	6.96e-05	0.00771	CbGpPWpGaD
Indomethacin—PPARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—ankylosing spondylitis	6.94e-05	0.00768	CbGpPWpGaD
Indomethacin—PLA2G2A—Spinal Cord Injury—TLR4—ankylosing spondylitis	6.91e-05	0.00765	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—IL1A—ankylosing spondylitis	6.86e-05	0.00759	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—CD40LG—ankylosing spondylitis	6.82e-05	0.00755	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—IL10—ankylosing spondylitis	6.82e-05	0.00755	CbGpPWpGaD
Indomethacin—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	6.66e-05	0.00737	CbGpPWpGaD
Indomethacin—CXCL8—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	6.62e-05	0.00733	CbGpPWpGaD
Indomethacin—PTGDR2—GPCR ligand binding—PTGER4—ankylosing spondylitis	6.62e-05	0.00733	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—HLA-B—ankylosing spondylitis	6.48e-05	0.00718	CbGpPWpGaD
Indomethacin—SLC22A7—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	6.33e-05	0.00701	CbGpPWpGaD
Indomethacin—PTGS1—tendon—ankylosing spondylitis	6.04e-05	0.00961	CbGeAlD
Indomethacin—PLA2G2A—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	6.01e-05	0.00666	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—HLA-A—ankylosing spondylitis	6.01e-05	0.00665	CbGpPWpGaD
Indomethacin—CXCL8—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	5.93e-05	0.00657	CbGpPWpGaD
Indomethacin—PTGS2—tendon—ankylosing spondylitis	5.77e-05	0.00918	CbGeAlD
Indomethacin—PPARG—Transcription factor regulation in adipogenesis—TNF—ankylosing spondylitis	5.68e-05	0.00629	CbGpPWpGaD
Indomethacin—Malaise—Methylprednisolone—ankylosing spondylitis	5.61e-05	0.00147	CcSEcCtD
Indomethacin—Vertigo—Triamcinolone—ankylosing spondylitis	5.6e-05	0.00147	CcSEcCtD
Indomethacin—Syncope—Triamcinolone—ankylosing spondylitis	5.59e-05	0.00146	CcSEcCtD
Indomethacin—Vertigo—Methylprednisolone—ankylosing spondylitis	5.59e-05	0.00146	CcSEcCtD
Indomethacin—Syncope—Methylprednisolone—ankylosing spondylitis	5.58e-05	0.00146	CcSEcCtD
Indomethacin—Oedema—Prednisolone—ankylosing spondylitis	5.53e-05	0.00145	CcSEcCtD
Indomethacin—Anaphylactic shock—Prednisolone—ankylosing spondylitis	5.53e-05	0.00145	CcSEcCtD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	5.53e-05	0.00612	CbGpPWpGaD
Indomethacin—Loss of consciousness—Triamcinolone—ankylosing spondylitis	5.48e-05	0.00143	CcSEcCtD
Indomethacin—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	5.46e-05	0.00143	CcSEcCtD
Indomethacin—CXCL8—Senescence and Autophagy in Cancer—IL1A—ankylosing spondylitis	5.46e-05	0.00605	CbGpPWpGaD
Indomethacin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—IL1A—ankylosing spondylitis	5.46e-05	0.00605	CbGpPWpGaD
Indomethacin—Shock—Prednisolone—ankylosing spondylitis	5.44e-05	0.00143	CcSEcCtD
Indomethacin—ABCC3—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.43e-05	0.00601	CbGpPWpGaD
Indomethacin—Convulsion—Triamcinolone—ankylosing spondylitis	5.4e-05	0.00141	CcSEcCtD
Indomethacin—Tachycardia—Prednisolone—ankylosing spondylitis	5.4e-05	0.00141	CcSEcCtD
Indomethacin—Convulsion—Methylprednisolone—ankylosing spondylitis	5.39e-05	0.00141	CcSEcCtD
Indomethacin—Hypertension—Triamcinolone—ankylosing spondylitis	5.38e-05	0.00141	CcSEcCtD
Indomethacin—Hypertension—Methylprednisolone—ankylosing spondylitis	5.37e-05	0.00141	CcSEcCtD
Indomethacin—Hyperhidrosis—Prednisolone—ankylosing spondylitis	5.35e-05	0.0014	CcSEcCtD
Indomethacin—SLC22A8—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.32e-05	0.00589	CbGpPWpGaD
Indomethacin—Anxiety—Methylprednisolone—ankylosing spondylitis	5.27e-05	0.00138	CcSEcCtD
Indomethacin—Drowsiness—Methotrexate—ankylosing spondylitis	5.27e-05	0.00138	CcSEcCtD
Indomethacin—Depression—Methotrexate—ankylosing spondylitis	5.25e-05	0.00138	CcSEcCtD
Indomethacin—Flushing—Prednisone—ankylosing spondylitis	5.25e-05	0.00138	CcSEcCtD
Indomethacin—Ill-defined disorder—Betamethasone—ankylosing spondylitis	5.25e-05	0.00137	CcSEcCtD
Indomethacin—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	5.25e-05	0.00137	CcSEcCtD
Indomethacin—Discomfort—Triamcinolone—ankylosing spondylitis	5.24e-05	0.00137	CcSEcCtD
Indomethacin—Discomfort—Methylprednisolone—ankylosing spondylitis	5.23e-05	0.00137	CcSEcCtD
Indomethacin—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	5.22e-05	0.00137	CcSEcCtD
Indomethacin—Renal failure—Methotrexate—ankylosing spondylitis	5.18e-05	0.00136	CcSEcCtD
Indomethacin—Angioedema—Dexamethasone—ankylosing spondylitis	5.17e-05	0.00135	CcSEcCtD
Indomethacin—Angioedema—Betamethasone—ankylosing spondylitis	5.17e-05	0.00135	CcSEcCtD
Indomethacin—Stomatitis—Methotrexate—ankylosing spondylitis	5.13e-05	0.00134	CcSEcCtD
Indomethacin—Confusional state—Methylprednisolone—ankylosing spondylitis	5.12e-05	0.00134	CcSEcCtD
Indomethacin—ABCC4—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.1e-05	0.00565	CbGpPWpGaD
Indomethacin—Malaise—Dexamethasone—ankylosing spondylitis	5.1e-05	0.00134	CcSEcCtD
Indomethacin—Malaise—Betamethasone—ankylosing spondylitis	5.1e-05	0.00134	CcSEcCtD
Indomethacin—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	5.09e-05	0.00133	CcSEcCtD
Indomethacin—Oedema—Triamcinolone—ankylosing spondylitis	5.09e-05	0.00133	CcSEcCtD
Indomethacin—Vertigo—Dexamethasone—ankylosing spondylitis	5.08e-05	0.00133	CcSEcCtD
Indomethacin—Vertigo—Betamethasone—ankylosing spondylitis	5.08e-05	0.00133	CcSEcCtD
Indomethacin—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	5.07e-05	0.00133	CcSEcCtD
Indomethacin—Syncope—Betamethasone—ankylosing spondylitis	5.07e-05	0.00133	CcSEcCtD
Indomethacin—Syncope—Dexamethasone—ankylosing spondylitis	5.07e-05	0.00133	CcSEcCtD
Indomethacin—Arrhythmia—Prednisone—ankylosing spondylitis	5.05e-05	0.00132	CcSEcCtD
Indomethacin—Sweating—Methotrexate—ankylosing spondylitis	5.05e-05	0.00132	CcSEcCtD
Indomethacin—Haematuria—Methotrexate—ankylosing spondylitis	5.02e-05	0.00132	CcSEcCtD
Indomethacin—Shock—Triamcinolone—ankylosing spondylitis	5e-05	0.00131	CcSEcCtD
Indomethacin—Insomnia—Prednisolone—ankylosing spondylitis	5e-05	0.00131	CcSEcCtD
Indomethacin—Alopecia—Prednisone—ankylosing spondylitis	5e-05	0.00131	CcSEcCtD
Indomethacin—Shock—Methylprednisolone—ankylosing spondylitis	4.99e-05	0.00131	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—IL1A—ankylosing spondylitis	4.97e-05	0.00551	CbGpPWpGaD
Indomethacin—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—ankylosing spondylitis	4.97e-05	0.00551	CbGpPWpGaD
Indomethacin—Loss of consciousness—Dexamethasone—ankylosing spondylitis	4.97e-05	0.0013	CcSEcCtD
Indomethacin—Loss of consciousness—Betamethasone—ankylosing spondylitis	4.97e-05	0.0013	CcSEcCtD
Indomethacin—Epistaxis—Methotrexate—ankylosing spondylitis	4.97e-05	0.0013	CcSEcCtD
Indomethacin—Paraesthesia—Prednisolone—ankylosing spondylitis	4.97e-05	0.0013	CcSEcCtD
Indomethacin—Tachycardia—Triamcinolone—ankylosing spondylitis	4.96e-05	0.0013	CcSEcCtD
Indomethacin—Tachycardia—Methylprednisolone—ankylosing spondylitis	4.95e-05	0.0013	CcSEcCtD
Indomethacin—Erythema—Prednisone—ankylosing spondylitis	4.92e-05	0.00129	CcSEcCtD
Indomethacin—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	4.92e-05	0.00129	CcSEcCtD
Indomethacin—Agranulocytosis—Methotrexate—ankylosing spondylitis	4.91e-05	0.00129	CcSEcCtD
Indomethacin—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	4.91e-05	0.00129	CcSEcCtD
Indomethacin—Convulsion—Dexamethasone—ankylosing spondylitis	4.9e-05	0.00128	CcSEcCtD
Indomethacin—Convulsion—Betamethasone—ankylosing spondylitis	4.9e-05	0.00128	CcSEcCtD
Indomethacin—Hypertension—Dexamethasone—ankylosing spondylitis	4.88e-05	0.00128	CcSEcCtD
Indomethacin—Hypertension—Betamethasone—ankylosing spondylitis	4.88e-05	0.00128	CcSEcCtD
Indomethacin—CXCL8—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	4.86e-05	0.00539	CbGpPWpGaD
Indomethacin—Anxiety—Dexamethasone—ankylosing spondylitis	4.8e-05	0.00126	CcSEcCtD
Indomethacin—Anxiety—Betamethasone—ankylosing spondylitis	4.8e-05	0.00126	CcSEcCtD
Indomethacin—Discomfort—Dexamethasone—ankylosing spondylitis	4.76e-05	0.00125	CcSEcCtD
Indomethacin—Discomfort—Betamethasone—ankylosing spondylitis	4.76e-05	0.00125	CcSEcCtD
Indomethacin—Haemoglobin—Methotrexate—ankylosing spondylitis	4.75e-05	0.00124	CcSEcCtD
Indomethacin—Hypotension—Methylprednisolone—ankylosing spondylitis	4.74e-05	0.00124	CcSEcCtD
Indomethacin—Pain—Prednisolone—ankylosing spondylitis	4.73e-05	0.00124	CcSEcCtD
Indomethacin—Hepatitis—Methotrexate—ankylosing spondylitis	4.73e-05	0.00124	CcSEcCtD
Indomethacin—Haemorrhage—Methotrexate—ankylosing spondylitis	4.73e-05	0.00124	CcSEcCtD
Indomethacin—SLCO1A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.72e-05	0.00523	CbGpPWpGaD
Indomethacin—Vision blurred—Prednisone—ankylosing spondylitis	4.64e-05	0.00122	CcSEcCtD
Indomethacin—Anaphylactic shock—Betamethasone—ankylosing spondylitis	4.61e-05	0.00121	CcSEcCtD
Indomethacin—Oedema—Dexamethasone—ankylosing spondylitis	4.61e-05	0.00121	CcSEcCtD
Indomethacin—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	4.61e-05	0.00121	CcSEcCtD
Indomethacin—Oedema—Betamethasone—ankylosing spondylitis	4.61e-05	0.00121	CcSEcCtD
Indomethacin—Insomnia—Triamcinolone—ankylosing spondylitis	4.6e-05	0.00121	CcSEcCtD
Indomethacin—Insomnia—Methylprednisolone—ankylosing spondylitis	4.59e-05	0.0012	CcSEcCtD
Indomethacin—Ill-defined disorder—Prednisone—ankylosing spondylitis	4.57e-05	0.0012	CcSEcCtD
Indomethacin—Paraesthesia—Triamcinolone—ankylosing spondylitis	4.57e-05	0.0012	CcSEcCtD
Indomethacin—Feeling abnormal—Prednisolone—ankylosing spondylitis	4.56e-05	0.00119	CcSEcCtD
Indomethacin—Paraesthesia—Methylprednisolone—ankylosing spondylitis	4.56e-05	0.00119	CcSEcCtD
Indomethacin—Anaemia—Prednisone—ankylosing spondylitis	4.55e-05	0.00119	CcSEcCtD
Indomethacin—Shock—Dexamethasone—ankylosing spondylitis	4.54e-05	0.00119	CcSEcCtD
Indomethacin—Shock—Betamethasone—ankylosing spondylitis	4.54e-05	0.00119	CcSEcCtD
Indomethacin—Dyspnoea—Triamcinolone—ankylosing spondylitis	4.53e-05	0.00119	CcSEcCtD
Indomethacin—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	4.52e-05	0.00118	CcSEcCtD
Indomethacin—Thrombocytopenia—Betamethasone—ankylosing spondylitis	4.52e-05	0.00118	CcSEcCtD
Indomethacin—Tachycardia—Betamethasone—ankylosing spondylitis	4.5e-05	0.00118	CcSEcCtD
Indomethacin—Tachycardia—Dexamethasone—ankylosing spondylitis	4.5e-05	0.00118	CcSEcCtD
Indomethacin—Angioedema—Prednisone—ankylosing spondylitis	4.5e-05	0.00118	CcSEcCtD
Indomethacin—CXCL8—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	4.48e-05	0.00496	CbGpPWpGaD
Indomethacin—Dyspepsia—Triamcinolone—ankylosing spondylitis	4.48e-05	0.00117	CcSEcCtD
Indomethacin—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	4.48e-05	0.00496	CbGpPWpGaD
Indomethacin—Erythema multiforme—Methotrexate—ankylosing spondylitis	4.47e-05	0.00117	CcSEcCtD
Indomethacin—Dyspepsia—Methylprednisolone—ankylosing spondylitis	4.47e-05	0.00117	CcSEcCtD
Indomethacin—Hyperhidrosis—Betamethasone—ankylosing spondylitis	4.46e-05	0.00117	CcSEcCtD
Indomethacin—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	4.46e-05	0.00117	CcSEcCtD
Indomethacin—Malaise—Prednisone—ankylosing spondylitis	4.44e-05	0.00116	CcSEcCtD
Indomethacin—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.44e-05	0.00492	CbGpPWpGaD
Indomethacin—Vertigo—Prednisone—ankylosing spondylitis	4.42e-05	0.00116	CcSEcCtD
Indomethacin—Syncope—Prednisone—ankylosing spondylitis	4.42e-05	0.00116	CcSEcCtD
Indomethacin—Tinnitus—Methotrexate—ankylosing spondylitis	4.41e-05	0.00115	CcSEcCtD
Indomethacin—Anorexia—Betamethasone—ankylosing spondylitis	4.4e-05	0.00115	CcSEcCtD
Indomethacin—Anorexia—Dexamethasone—ankylosing spondylitis	4.4e-05	0.00115	CcSEcCtD
Indomethacin—Urticaria—Prednisolone—ankylosing spondylitis	4.39e-05	0.00115	CcSEcCtD
Indomethacin—Fatigue—Triamcinolone—ankylosing spondylitis	4.38e-05	0.00115	CcSEcCtD
Indomethacin—Fatigue—Methylprednisolone—ankylosing spondylitis	4.37e-05	0.00115	CcSEcCtD
Indomethacin—Pain—Triamcinolone—ankylosing spondylitis	4.35e-05	0.00114	CcSEcCtD
Indomethacin—Loss of consciousness—Prednisone—ankylosing spondylitis	4.33e-05	0.00113	CcSEcCtD
Indomethacin—Hypotension—Betamethasone—ankylosing spondylitis	4.31e-05	0.00113	CcSEcCtD
Indomethacin—Hypotension—Dexamethasone—ankylosing spondylitis	4.31e-05	0.00113	CcSEcCtD
Indomethacin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	4.31e-05	0.00477	CbGpPWpGaD
Indomethacin—ABCC2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.3e-05	0.00476	CbGpPWpGaD
Indomethacin—PLA2G2A—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	4.28e-05	0.00474	CbGpPWpGaD
Indomethacin—Convulsion—Prednisone—ankylosing spondylitis	4.27e-05	0.00112	CcSEcCtD
Indomethacin—Hypertension—Prednisone—ankylosing spondylitis	4.25e-05	0.00111	CcSEcCtD
Indomethacin—ABCC1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.25e-05	0.00471	CbGpPWpGaD
Indomethacin—Feeling abnormal—Triamcinolone—ankylosing spondylitis	4.19e-05	0.0011	CcSEcCtD
Indomethacin—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	4.18e-05	0.0011	CcSEcCtD
Indomethacin—Anxiety—Prednisone—ankylosing spondylitis	4.18e-05	0.00109	CcSEcCtD
Indomethacin—Alopecia—Methotrexate—ankylosing spondylitis	4.18e-05	0.00109	CcSEcCtD
Indomethacin—Insomnia—Dexamethasone—ankylosing spondylitis	4.17e-05	0.00109	CcSEcCtD
Indomethacin—Insomnia—Betamethasone—ankylosing spondylitis	4.17e-05	0.00109	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	4.15e-05	0.00109	CcSEcCtD
Indomethacin—Paraesthesia—Betamethasone—ankylosing spondylitis	4.14e-05	0.00109	CcSEcCtD
Indomethacin—Paraesthesia—Dexamethasone—ankylosing spondylitis	4.14e-05	0.00109	CcSEcCtD
Indomethacin—Discomfort—Prednisone—ankylosing spondylitis	4.14e-05	0.00109	CcSEcCtD
Indomethacin—Erythema—Methotrexate—ankylosing spondylitis	4.12e-05	0.00108	CcSEcCtD
Indomethacin—Hypersensitivity—Prednisolone—ankylosing spondylitis	4.07e-05	0.00107	CcSEcCtD
Indomethacin—Dyspepsia—Dexamethasone—ankylosing spondylitis	4.06e-05	0.00106	CcSEcCtD
Indomethacin—Dyspepsia—Betamethasone—ankylosing spondylitis	4.06e-05	0.00106	CcSEcCtD
Indomethacin—Urticaria—Triamcinolone—ankylosing spondylitis	4.04e-05	0.00106	CcSEcCtD
Indomethacin—SLCO1B1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	4.04e-05	0.00447	CbGpPWpGaD
Indomethacin—Urticaria—Methylprednisolone—ankylosing spondylitis	4.03e-05	0.00106	CcSEcCtD
Indomethacin—Body temperature increased—Triamcinolone—ankylosing spondylitis	4.02e-05	0.00105	CcSEcCtD
Indomethacin—Anaphylactic shock—Prednisone—ankylosing spondylitis	4.02e-05	0.00105	CcSEcCtD
Indomethacin—Oedema—Prednisone—ankylosing spondylitis	4.02e-05	0.00105	CcSEcCtD
Indomethacin—Abdominal pain—Methylprednisolone—ankylosing spondylitis	4.01e-05	0.00105	CcSEcCtD
Indomethacin—Decreased appetite—Dexamethasone—ankylosing spondylitis	4.01e-05	0.00105	CcSEcCtD
Indomethacin—Decreased appetite—Betamethasone—ankylosing spondylitis	4.01e-05	0.00105	CcSEcCtD
Indomethacin—CXCL8—Spinal Cord Injury—TLR4—ankylosing spondylitis	3.99e-05	0.00441	CbGpPWpGaD
Indomethacin—Fatigue—Betamethasone—ankylosing spondylitis	3.98e-05	0.00104	CcSEcCtD
Indomethacin—Fatigue—Dexamethasone—ankylosing spondylitis	3.98e-05	0.00104	CcSEcCtD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	3.98e-05	0.00441	CbGpPWpGaD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	3.96e-05	0.00438	CbGpPWpGaD
Indomethacin—Shock—Prednisone—ankylosing spondylitis	3.95e-05	0.00104	CcSEcCtD
Indomethacin—Pain—Betamethasone—ankylosing spondylitis	3.95e-05	0.00103	CcSEcCtD
Indomethacin—Pain—Dexamethasone—ankylosing spondylitis	3.95e-05	0.00103	CcSEcCtD
Indomethacin—Tachycardia—Prednisone—ankylosing spondylitis	3.92e-05	0.00103	CcSEcCtD
Indomethacin—Hyperhidrosis—Prednisone—ankylosing spondylitis	3.88e-05	0.00102	CcSEcCtD
Indomethacin—Vision blurred—Methotrexate—ankylosing spondylitis	3.88e-05	0.00102	CcSEcCtD
Indomethacin—Anorexia—Prednisone—ankylosing spondylitis	3.83e-05	0.001	CcSEcCtD
Indomethacin—Ill-defined disorder—Methotrexate—ankylosing spondylitis	3.82e-05	0.001	CcSEcCtD
Indomethacin—Anaemia—Methotrexate—ankylosing spondylitis	3.8e-05	0.000996	CcSEcCtD
Indomethacin—Feeling abnormal—Dexamethasone—ankylosing spondylitis	3.8e-05	0.000996	CcSEcCtD
Indomethacin—Feeling abnormal—Betamethasone—ankylosing spondylitis	3.8e-05	0.000996	CcSEcCtD
Indomethacin—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	3.77e-05	0.000989	CcSEcCtD
Indomethacin—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	3.77e-05	0.000989	CcSEcCtD
Indomethacin—Hypersensitivity—Triamcinolone—ankylosing spondylitis	3.75e-05	0.000982	CcSEcCtD
Indomethacin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	3.74e-05	0.00414	CbGpPWpGaD
Indomethacin—PTGDR2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	3.74e-05	0.00414	CbGpPWpGaD
Indomethacin—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	3.74e-05	0.000979	CcSEcCtD
Indomethacin—Malaise—Methotrexate—ankylosing spondylitis	3.71e-05	0.000972	CcSEcCtD
Indomethacin—Vertigo—Methotrexate—ankylosing spondylitis	3.7e-05	0.000969	CcSEcCtD
Indomethacin—Leukopenia—Methotrexate—ankylosing spondylitis	3.68e-05	0.000965	CcSEcCtD
Indomethacin—Urticaria—Betamethasone—ankylosing spondylitis	3.67e-05	0.00096	CcSEcCtD
Indomethacin—Urticaria—Dexamethasone—ankylosing spondylitis	3.67e-05	0.00096	CcSEcCtD
Indomethacin—Dizziness—Prednisolone—ankylosing spondylitis	3.66e-05	0.000958	CcSEcCtD
Indomethacin—Asthenia—Triamcinolone—ankylosing spondylitis	3.65e-05	0.000956	CcSEcCtD
Indomethacin—Abdominal pain—Dexamethasone—ankylosing spondylitis	3.65e-05	0.000956	CcSEcCtD
Indomethacin—Abdominal pain—Betamethasone—ankylosing spondylitis	3.65e-05	0.000956	CcSEcCtD
Indomethacin—Body temperature increased—Dexamethasone—ankylosing spondylitis	3.65e-05	0.000956	CcSEcCtD
Indomethacin—Body temperature increased—Betamethasone—ankylosing spondylitis	3.65e-05	0.000956	CcSEcCtD
Indomethacin—Asthenia—Methylprednisolone—ankylosing spondylitis	3.64e-05	0.000954	CcSEcCtD
Indomethacin—Insomnia—Prednisone—ankylosing spondylitis	3.63e-05	0.000952	CcSEcCtD
Indomethacin—Paraesthesia—Prednisone—ankylosing spondylitis	3.61e-05	0.000945	CcSEcCtD
Indomethacin—Pruritus—Triamcinolone—ankylosing spondylitis	3.6e-05	0.000943	CcSEcCtD
Indomethacin—Pruritus—Methylprednisolone—ankylosing spondylitis	3.59e-05	0.000941	CcSEcCtD
Indomethacin—Convulsion—Methotrexate—ankylosing spondylitis	3.57e-05	0.000934	CcSEcCtD
Indomethacin—PTGS2—Overview of nanoparticle effects—TNF—ankylosing spondylitis	3.55e-05	0.00394	CbGpPWpGaD
Indomethacin—Dyspepsia—Prednisone—ankylosing spondylitis	3.54e-05	0.000927	CcSEcCtD
Indomethacin—Chest pain—Methotrexate—ankylosing spondylitis	3.5e-05	0.000918	CcSEcCtD
Indomethacin—AKR1C3—Disease—ANTXR2—ankylosing spondylitis	3.5e-05	0.00388	CbGpPWpGaD
Indomethacin—CXCL8—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	3.5e-05	0.00387	CbGpPWpGaD
Indomethacin—Decreased appetite—Prednisone—ankylosing spondylitis	3.49e-05	0.000915	CcSEcCtD
Indomethacin—Rash—Prednisolone—ankylosing spondylitis	3.49e-05	0.000914	CcSEcCtD
Indomethacin—Dermatitis—Prednisolone—ankylosing spondylitis	3.48e-05	0.000913	CcSEcCtD
Indomethacin—Diarrhoea—Methylprednisolone—ankylosing spondylitis	3.47e-05	0.00091	CcSEcCtD
Indomethacin—Fatigue—Prednisone—ankylosing spondylitis	3.46e-05	0.000908	CcSEcCtD
Indomethacin—Headache—Prednisolone—ankylosing spondylitis	3.46e-05	0.000908	CcSEcCtD
Indomethacin—Discomfort—Methotrexate—ankylosing spondylitis	3.46e-05	0.000907	CcSEcCtD
Indomethacin—CXCL8—Cellular Senescence—IL1A—ankylosing spondylitis	3.46e-05	0.00383	CbGpPWpGaD
Indomethacin—Constipation—Prednisone—ankylosing spondylitis	3.44e-05	0.0009	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	3.4e-05	0.00377	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling by GPCR—PTGER4—ankylosing spondylitis	3.4e-05	0.00376	CbGpPWpGaD
Indomethacin—Confusional state—Methotrexate—ankylosing spondylitis	3.39e-05	0.000887	CcSEcCtD
Indomethacin—CXCL8—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	3.38e-05	0.00375	CbGpPWpGaD
Indomethacin—Dizziness—Triamcinolone—ankylosing spondylitis	3.36e-05	0.000881	CcSEcCtD
Indomethacin—Anaphylactic shock—Methotrexate—ankylosing spondylitis	3.36e-05	0.00088	CcSEcCtD
Indomethacin—Dizziness—Methylprednisolone—ankylosing spondylitis	3.36e-05	0.000879	CcSEcCtD
Indomethacin—Feeling abnormal—Prednisone—ankylosing spondylitis	3.31e-05	0.000868	CcSEcCtD
Indomethacin—Asthenia—Dexamethasone—ankylosing spondylitis	3.31e-05	0.000867	CcSEcCtD
Indomethacin—Asthenia—Betamethasone—ankylosing spondylitis	3.31e-05	0.000867	CcSEcCtD
Indomethacin—Thrombocytopenia—Methotrexate—ankylosing spondylitis	3.29e-05	0.000862	CcSEcCtD
Indomethacin—Gastrointestinal pain—Prednisone—ankylosing spondylitis	3.29e-05	0.000861	CcSEcCtD
Indomethacin—Nausea—Prednisolone—ankylosing spondylitis	3.28e-05	0.000861	CcSEcCtD
Indomethacin—Pruritus—Dexamethasone—ankylosing spondylitis	3.26e-05	0.000855	CcSEcCtD
Indomethacin—Pruritus—Betamethasone—ankylosing spondylitis	3.26e-05	0.000855	CcSEcCtD
Indomethacin—PLA2G2A—Spinal Cord Injury—TNF—ankylosing spondylitis	3.26e-05	0.00361	CbGpPWpGaD
Indomethacin—Hyperhidrosis—Methotrexate—ankylosing spondylitis	3.25e-05	0.000851	CcSEcCtD
Indomethacin—Vomiting—Triamcinolone—ankylosing spondylitis	3.23e-05	0.000847	CcSEcCtD
Indomethacin—Vomiting—Methylprednisolone—ankylosing spondylitis	3.23e-05	0.000845	CcSEcCtD
Indomethacin—Rash—Triamcinolone—ankylosing spondylitis	3.21e-05	0.00084	CcSEcCtD
Indomethacin—Dermatitis—Triamcinolone—ankylosing spondylitis	3.2e-05	0.000839	CcSEcCtD
Indomethacin—Anorexia—Methotrexate—ankylosing spondylitis	3.2e-05	0.000839	CcSEcCtD
Indomethacin—Rash—Methylprednisolone—ankylosing spondylitis	3.2e-05	0.000838	CcSEcCtD
Indomethacin—Dermatitis—Methylprednisolone—ankylosing spondylitis	3.2e-05	0.000837	CcSEcCtD
Indomethacin—Urticaria—Prednisone—ankylosing spondylitis	3.19e-05	0.000836	CcSEcCtD
Indomethacin—Headache—Triamcinolone—ankylosing spondylitis	3.19e-05	0.000835	CcSEcCtD
Indomethacin—Headache—Methylprednisolone—ankylosing spondylitis	3.18e-05	0.000833	CcSEcCtD
Indomethacin—Abdominal pain—Prednisone—ankylosing spondylitis	3.18e-05	0.000832	CcSEcCtD
Indomethacin—Body temperature increased—Prednisone—ankylosing spondylitis	3.18e-05	0.000832	CcSEcCtD
Indomethacin—Diarrhoea—Dexamethasone—ankylosing spondylitis	3.16e-05	0.000827	CcSEcCtD
Indomethacin—Diarrhoea—Betamethasone—ankylosing spondylitis	3.16e-05	0.000827	CcSEcCtD
Indomethacin—Hypotension—Methotrexate—ankylosing spondylitis	3.14e-05	0.000822	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	3.11e-05	0.00345	CbGpPWpGaD
Indomethacin—Dizziness—Dexamethasone—ankylosing spondylitis	3.05e-05	0.000799	CcSEcCtD
Indomethacin—Dizziness—Betamethasone—ankylosing spondylitis	3.05e-05	0.000799	CcSEcCtD
Indomethacin—Insomnia—Methotrexate—ankylosing spondylitis	3.04e-05	0.000796	CcSEcCtD
Indomethacin—Nausea—Triamcinolone—ankylosing spondylitis	3.02e-05	0.000791	CcSEcCtD
Indomethacin—Paraesthesia—Methotrexate—ankylosing spondylitis	3.02e-05	0.00079	CcSEcCtD
Indomethacin—Nausea—Methylprednisolone—ankylosing spondylitis	3.01e-05	0.00079	CcSEcCtD
Indomethacin—Dyspnoea—Methotrexate—ankylosing spondylitis	2.99e-05	0.000784	CcSEcCtD
Indomethacin—Somnolence—Methotrexate—ankylosing spondylitis	2.99e-05	0.000782	CcSEcCtD
Indomethacin—Hypersensitivity—Prednisone—ankylosing spondylitis	2.96e-05	0.000776	CcSEcCtD
Indomethacin—Dyspepsia—Methotrexate—ankylosing spondylitis	2.96e-05	0.000775	CcSEcCtD
Indomethacin—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	2.95e-05	0.00326	CbGpPWpGaD
Indomethacin—Vomiting—Dexamethasone—ankylosing spondylitis	2.93e-05	0.000769	CcSEcCtD
Indomethacin—Vomiting—Betamethasone—ankylosing spondylitis	2.93e-05	0.000769	CcSEcCtD
Indomethacin—Decreased appetite—Methotrexate—ankylosing spondylitis	2.92e-05	0.000765	CcSEcCtD
Indomethacin—PPARA—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	2.91e-05	0.00322	CbGpPWpGaD
Indomethacin—Rash—Betamethasone—ankylosing spondylitis	2.91e-05	0.000762	CcSEcCtD
Indomethacin—Rash—Dexamethasone—ankylosing spondylitis	2.91e-05	0.000762	CcSEcCtD
Indomethacin—Dermatitis—Dexamethasone—ankylosing spondylitis	2.91e-05	0.000762	CcSEcCtD
Indomethacin—Dermatitis—Betamethasone—ankylosing spondylitis	2.91e-05	0.000762	CcSEcCtD
Indomethacin—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	2.9e-05	0.00321	CbGpPWpGaD
Indomethacin—Fatigue—Methotrexate—ankylosing spondylitis	2.9e-05	0.000759	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	2.89e-05	0.00321	CbGpPWpGaD
Indomethacin—Headache—Dexamethasone—ankylosing spondylitis	2.89e-05	0.000757	CcSEcCtD
Indomethacin—Headache—Betamethasone—ankylosing spondylitis	2.89e-05	0.000757	CcSEcCtD
Indomethacin—Asthenia—Prednisone—ankylosing spondylitis	2.88e-05	0.000755	CcSEcCtD
Indomethacin—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	2.88e-05	0.00319	CbGpPWpGaD
Indomethacin—Pain—Methotrexate—ankylosing spondylitis	2.87e-05	0.000752	CcSEcCtD
Indomethacin—Pruritus—Prednisone—ankylosing spondylitis	2.84e-05	0.000745	CcSEcCtD
Indomethacin—Feeling abnormal—Methotrexate—ankylosing spondylitis	2.77e-05	0.000725	CcSEcCtD
Indomethacin—Diarrhoea—Prednisone—ankylosing spondylitis	2.75e-05	0.00072	CcSEcCtD
Indomethacin—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	2.75e-05	0.00072	CcSEcCtD
Indomethacin—Nausea—Dexamethasone—ankylosing spondylitis	2.74e-05	0.000718	CcSEcCtD
Indomethacin—Nausea—Betamethasone—ankylosing spondylitis	2.74e-05	0.000718	CcSEcCtD
Indomethacin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.71e-05	0.003	CbGpPWpGaD
Indomethacin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.71e-05	0.003	CbGpPWpGaD
Indomethacin—Urticaria—Methotrexate—ankylosing spondylitis	2.67e-05	0.000699	CcSEcCtD
Indomethacin—Dizziness—Prednisone—ankylosing spondylitis	2.66e-05	0.000696	CcSEcCtD
Indomethacin—Body temperature increased—Methotrexate—ankylosing spondylitis	2.65e-05	0.000696	CcSEcCtD
Indomethacin—Abdominal pain—Methotrexate—ankylosing spondylitis	2.65e-05	0.000696	CcSEcCtD
Indomethacin—CXCL8—Metabolism of proteins—B3GNT2—ankylosing spondylitis	2.64e-05	0.00293	CbGpPWpGaD
Indomethacin—CXCL8—Cellular responses to stress—IL1A—ankylosing spondylitis	2.61e-05	0.00289	CbGpPWpGaD
Indomethacin—CXCL8—Allograft Rejection—TNF—ankylosing spondylitis	2.59e-05	0.00287	CbGpPWpGaD
Indomethacin—CXCL8—GPCR ligand binding—PTGER4—ankylosing spondylitis	2.58e-05	0.00285	CbGpPWpGaD
Indomethacin—Vomiting—Prednisone—ankylosing spondylitis	2.56e-05	0.000669	CcSEcCtD
Indomethacin—Rash—Prednisone—ankylosing spondylitis	2.53e-05	0.000664	CcSEcCtD
Indomethacin—Dermatitis—Prednisone—ankylosing spondylitis	2.53e-05	0.000663	CcSEcCtD
Indomethacin—Headache—Prednisone—ankylosing spondylitis	2.52e-05	0.00066	CcSEcCtD
Indomethacin—Hypersensitivity—Methotrexate—ankylosing spondylitis	2.47e-05	0.000648	CcSEcCtD
Indomethacin—PTGDR2—Signaling by GPCR—MMP3—ankylosing spondylitis	2.42e-05	0.00268	CbGpPWpGaD
Indomethacin—Asthenia—Methotrexate—ankylosing spondylitis	2.41e-05	0.000631	CcSEcCtD
Indomethacin—Nausea—Prednisone—ankylosing spondylitis	2.39e-05	0.000625	CcSEcCtD
Indomethacin—Pruritus—Methotrexate—ankylosing spondylitis	2.38e-05	0.000623	CcSEcCtD
Indomethacin—PLA2G2A—Metabolism—B3GNT2—ankylosing spondylitis	2.36e-05	0.00262	CbGpPWpGaD
Indomethacin—ALB—Folate Metabolism—CRP—ankylosing spondylitis	2.35e-05	0.0026	CbGpPWpGaD
Indomethacin—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.31e-05	0.00256	CbGpPWpGaD
Indomethacin—PTGS2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	2.3e-05	0.00255	CbGpPWpGaD
Indomethacin—Diarrhoea—Methotrexate—ankylosing spondylitis	2.3e-05	0.000602	CcSEcCtD
Indomethacin—PPARG—Signaling events mediated by HDAC Class I—TNF—ankylosing spondylitis	2.25e-05	0.00249	CbGpPWpGaD
Indomethacin—Dizziness—Methotrexate—ankylosing spondylitis	2.22e-05	0.000582	CcSEcCtD
Indomethacin—PTGS2—Spinal Cord Injury—IL1A—ankylosing spondylitis	2.18e-05	0.00241	CbGpPWpGaD
Indomethacin—Vomiting—Methotrexate—ankylosing spondylitis	2.14e-05	0.000559	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	2.13e-05	0.00236	CbGpPWpGaD
Indomethacin—Rash—Methotrexate—ankylosing spondylitis	2.12e-05	0.000555	CcSEcCtD
Indomethacin—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	2.12e-05	0.00234	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	2.12e-05	0.00234	CbGpPWpGaD
Indomethacin—Dermatitis—Methotrexate—ankylosing spondylitis	2.12e-05	0.000554	CcSEcCtD
Indomethacin—CXCL8—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	2.11e-05	0.00234	CbGpPWpGaD
Indomethacin—Headache—Methotrexate—ankylosing spondylitis	2.1e-05	0.000551	CcSEcCtD
Indomethacin—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—ankylosing spondylitis	2.09e-05	0.00231	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—B3GNT2—ankylosing spondylitis	2.06e-05	0.00228	CbGpPWpGaD
Indomethacin—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.02e-05	0.00224	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	2.01e-05	0.00223	CbGpPWpGaD
Indomethacin—SLC10A1—Metabolism—B3GNT2—ankylosing spondylitis	2.01e-05	0.00222	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—PTGER4—ankylosing spondylitis	2.01e-05	0.00222	CbGpPWpGaD
Indomethacin—Nausea—Methotrexate—ankylosing spondylitis	1.99e-05	0.000523	CcSEcCtD
Indomethacin—PPARA—Adipogenesis—TNF—ankylosing spondylitis	1.91e-05	0.00212	CbGpPWpGaD
Indomethacin—CXCL8—Spinal Cord Injury—TNF—ankylosing spondylitis	1.88e-05	0.00208	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	1.87e-05	0.00207	CbGpPWpGaD
Indomethacin—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	1.86e-05	0.00206	CbGpPWpGaD
Indomethacin—ABCC1—Disease—ANTXR2—ankylosing spondylitis	1.8e-05	0.002	CbGpPWpGaD
Indomethacin—PTGS2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	1.75e-05	0.00194	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—TLR4—ankylosing spondylitis	1.75e-05	0.00193	CbGpPWpGaD
Indomethacin—AKR1C3—Metabolism—B3GNT2—ankylosing spondylitis	1.73e-05	0.00191	CbGpPWpGaD
Indomethacin—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	1.65e-05	0.00183	CbGpPWpGaD
Indomethacin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	1.64e-05	0.00181	CbGpPWpGaD
Indomethacin—CXCL8—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	1.51e-05	0.00167	CbGpPWpGaD
Indomethacin—PPARA—Metabolism—B3GNT2—ankylosing spondylitis	1.5e-05	0.00166	CbGpPWpGaD
Indomethacin—CXCL8—GPCR downstream signaling—PTGER4—ankylosing spondylitis	1.46e-05	0.00161	CbGpPWpGaD
Indomethacin—PTGDR2—Signaling Pathways—MMP3—ankylosing spondylitis	1.43e-05	0.00158	CbGpPWpGaD
Indomethacin—PPARG—Adipogenesis—TNF—ankylosing spondylitis	1.37e-05	0.00152	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.32e-05	0.00146	CbGpPWpGaD
Indomethacin—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	1.31e-05	0.00145	CbGpPWpGaD
Indomethacin—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	1.3e-05	0.00145	CbGpPWpGaD
Indomethacin—PTGS2—Disease—ANTXR2—ankylosing spondylitis	1.21e-05	0.00134	CbGpPWpGaD
Indomethacin—ABCC3—Metabolism—B3GNT2—ankylosing spondylitis	1.13e-05	0.00126	CbGpPWpGaD
Indomethacin—UGT2B7—Metabolism—B3GNT2—ankylosing spondylitis	1.13e-05	0.00126	CbGpPWpGaD
Indomethacin—PPARG—Metabolism—B3GNT2—ankylosing spondylitis	1.07e-05	0.00119	CbGpPWpGaD
Indomethacin—ABCC1—Disease—B3GNT2—ankylosing spondylitis	1.06e-05	0.00118	CbGpPWpGaD
Indomethacin—ALB—Folate Metabolism—TNF—ankylosing spondylitis	1.06e-05	0.00118	CbGpPWpGaD
Indomethacin—PTGS2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	1.04e-05	0.00115	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—PTGER4—ankylosing spondylitis	9.91e-06	0.0011	CbGpPWpGaD
Indomethacin—SLCO1A2—Metabolism—B3GNT2—ankylosing spondylitis	9.88e-06	0.00109	CbGpPWpGaD
Indomethacin—CXCL8—Signaling by GPCR—MMP3—ankylosing spondylitis	9.42e-06	0.00104	CbGpPWpGaD
Indomethacin—UGT1A9—Metabolism—B3GNT2—ankylosing spondylitis	9.22e-06	0.00102	CbGpPWpGaD
Indomethacin—UGT1A1—Metabolism—B3GNT2—ankylosing spondylitis	9.22e-06	0.00102	CbGpPWpGaD
Indomethacin—ABCC1—Metabolism—B3GNT2—ankylosing spondylitis	8.89e-06	0.000985	CbGpPWpGaD
Indomethacin—SLCO1B1—Metabolism—B3GNT2—ankylosing spondylitis	8.45e-06	0.000936	CbGpPWpGaD
Indomethacin—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	8.43e-06	0.000934	CbGpPWpGaD
Indomethacin—AKR1C3—Disease—HLA-A—ankylosing spondylitis	8.35e-06	0.000924	CbGpPWpGaD
Indomethacin—PTGS2—Spinal Cord Injury—TNF—ankylosing spondylitis	8.24e-06	0.000913	CbGpPWpGaD
Indomethacin—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	8.06e-06	0.000892	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—PTGER4—ankylosing spondylitis	7.81e-06	0.000865	CbGpPWpGaD
Indomethacin—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	7.52e-06	0.000833	CbGpPWpGaD
Indomethacin—PTGS2—Disease—B3GNT2—ankylosing spondylitis	7.13e-06	0.000789	CbGpPWpGaD
Indomethacin—AKR1C3—Signaling Pathways—MMP3—ankylosing spondylitis	7.05e-06	0.000781	CbGpPWpGaD
Indomethacin—PPARA—Developmental Biology—TNF—ankylosing spondylitis	6.58e-06	0.000729	CbGpPWpGaD
Indomethacin—PTGS2—Metabolism—B3GNT2—ankylosing spondylitis	5.97e-06	0.000661	CbGpPWpGaD
Indomethacin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	5.61e-06	0.000621	CbGpPWpGaD
Indomethacin—CXCL8—Signaling Pathways—MMP3—ankylosing spondylitis	5.56e-06	0.000616	CbGpPWpGaD
Indomethacin—ALB—Metabolism—B3GNT2—ankylosing spondylitis	4.83e-06	0.000535	CbGpPWpGaD
Indomethacin—PPARG—Developmental Biology—TNF—ankylosing spondylitis	4.72e-06	0.000522	CbGpPWpGaD
Indomethacin—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	4.33e-06	0.00048	CbGpPWpGaD
Indomethacin—ABCC1—Disease—HLA-A—ankylosing spondylitis	4.3e-06	0.000476	CbGpPWpGaD
Indomethacin—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	4.23e-06	0.000469	CbGpPWpGaD
Indomethacin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.98e-06	0.00044	CbGpPWpGaD
Indomethacin—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	3.95e-06	0.000438	CbGpPWpGaD
Indomethacin—PTGS2—Disease—HLA-A—ankylosing spondylitis	2.88e-06	0.000319	CbGpPWpGaD
